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ABSTRACT
Susceptibility patterns of Streptococcus pneumoniae
and Haemophilus inﬂuenzae collected over a 5-year
period in a Beirut general university hospital
were studied. Only 40.6–50% of S. pneumoniae
isolates were susceptible to penicillin G. Suscep-
tibility to clindamycin and erythromycin de-
creased from 94.1% and 89.7%, respectively, in
2000 to 75% and 71.9%, respectively, in 2004. All
isolates were susceptible to ceftriaxone, ciproﬂ-
oxacin and vancomycin. For H. inﬂuenzae, no
resistance was observed to amoxycillin-clavula-
nate, ceftriaxone, ciproﬂoxacin and rifampicin,
with >92% of isolates showing susceptibility to
cefuroxime, chloramphenicol, erythromycin and
tetracycline. The proportion of b-lactamase-posit-
ive isolates varied between 22.7 and 30.8%.
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Streptococcus pneumoniae and Haemophilus inﬂuen-
zae are among the bacteria isolatedmost frequently
from community-acquired respiratory tract infec-
tions [1–3]. Global penicillin resistance rates for
S. pneumoniae range from 5.8 to 54% [4], and
resistance to macrolides and quinolones is also
increasing [4,5]. Similarly, up to 40% of H. inﬂuen-
zae isolates now produce b-lactamase [6–8]. Con-
sequently, there is a need to survey national and
local changes in antimicrobial susceptibility pat-
terns in order to monitor the increase in resistance,
provide better therapy for patients, and maintain
the effectiveness of available drugs. In Lebanon,
information concerning antimicrobial susceptibil-
ity patterns remains scarce, and is limited to a few
hospitals and health centres where a handful of
studies have been conducted [9,10]. The present
report provides data concerning the susceptibility
proﬁles of S. pneumoniae and H. inﬂuenzae isolates
during a 5-year period at St. George Hospital,
Beirut, which is a 400-bed university medical
centre with 10 000–12 000 patients per year.
Between 1 January 2000 and 31 December 2004,
248 isolates of S. pneumoniae and 326 isolates of
H. inﬂuenzaewere collected prospectively. A labor-
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atory coding system was used to prevent the
acquisition of duplicate isolates with the same
antimicrobial resistance pattern from the same
patient and site of infection within a period of
1 year. Processing of clinical specimens and bac-
terial isolation and identiﬁcation were performed
according to conventional microbiological meth-
ods. Susceptibility testing was performed accord-
ing to NCCLS recommendations and breakpoints
[11,12]. The control strainsusedwereS. pneumoniae
ATCC 49619, H. inﬂuenzae ATCC 49247 and H. in-
ﬂuenzae ATCC 49766. All quality control values
were within acceptable limits. b-Lactamase pro-
duction byH. inﬂuenzae isolates was detected with
nitroceﬁn disks (Becton Dickinson, Cockeysville,
MD, USA). In general, non-meningitis breakpoints
were adopted; only two isolates (one H. inﬂuenzae
in 2003 and one S. pneumoniae in 2002) were from
cerebrospinal ﬂuid. The non-meningitic pneumo-
coccal breakpoints for ceftriaxone were: sensitive
(£1 mg ⁄L), intermediate (2 mg ⁄L), and resistant
(‡4 mg ⁄L). b-Lactamase-negative, ampicillin-
resistant (BLNAR) isolates were deﬁned as
b-lactamase-negative isolates with an ampicillin
MIC ‡ 4 mg ⁄L, but this deﬁnition is only prelim-
inary without PBP3 analysis. Since no breakpoints
for erythromycin and H. inﬂuenzae have been
approved by the NCCLS, the breakpoints recom-
mended for clarithromycin were used.
During the 5-year study period, 304 (53%) male
and 270 (47%) female patientswere included in the
study. Most patients from whom S. pneumoniae
and H. inﬂuenzae were isolated were outpatients,
with a 5-year mean of 42.4% for S. pneumoniae and
56.9% for H. inﬂuenzae. This conﬁrms previous
ﬁndings that most infections caused by H. inﬂuen-
zae and S. pneumoniae are community-acquired.
For both organisms, the most frequent site of
Table 1. Antimicrobial susceptibilities and MICs for 248 isolates of Streptococcus pneumoniae from the Saint George
Hospital, Beirut, between 2000 and 2004, grouped according to susceptibility to Penicillin G
Antibiotic Year # isolates
All isolates Penicillin G-susceptible Penicillin G-intermediate Penicillin G-resistant
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) % susceptible
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) % susceptible
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) % susceptible
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) % susceptible
Ceftriaxone 2000 71 100 100 100 100
2001 50 100 100 100 100
2002 56 100 100 100 100
2003 37 0.03 0.03 100 £0.015 0.03 100 0.015 0.25 100 0.03 0.5 100
2004 34 0.03 0.03 100 £0.016 0.03 100 0.03 0.25 100 0.06 0.5 100
Clindamycin 2000 71 94.1 98.6 95.7 80.5
2001 50 91.8 94.6 91.2 78.6
2002 56 82.1 92.2 90.1 77.2
2003 37 0.03 0.12 78.4 0.015 0.12 88.6 0.06 0.12 81.7 0.06 4 69.9
2004 34 0.03 0.12 75.0 0.015 0.12 85.4 0.06 0.12 75.2 0.06 4 62.8
Erythromycin 2000 71 89.7 98.7 74.1 41.5
2001 50 89.9 97.6 77.3 42.9
2002 56 76.8 86.6 69.8 33.6
2003 37 0.06 4 73.0 0.06 0.06 85.7 0.06 16 69.7 4 >64 31.8
2004 34 0.06 4 71.9 0.06 0.06 79.9 0.12 16 68.6 4 >64 29.7
Ciproﬂoxacin 2000 71 100 100 100 100
2001 50 100 100 100 100
2002 56 100 100 100 100
2003 37 0.5 0.5 100 – – 100 – – 100 – – 100
2004 34 0.5 0.5 100 – – 100 – – 100 – – 100
Penicillin 2000 71 50.0 100 0.0 0.0
2001 50 44.4 100 0.0 0.0
2002 56 45.5 100 0.0 0.0
2003 37 0.03 4 38.9 0.03 0.06 100 0.25 1 0.0 4 4 0.0
2004 34 0.03 3 40.6 0.03 0.06 100 0.25 2 0.0 4 4 0.0
Tetracycline 2000 71 95.5 99.5 76.2 31.4
2001 50 95 98.6 76.3 35.6
2002 56 92.9 99.7 77.5 31.4
2003 37 0.25 0.5 90.6 0.25 0.25 94.5 0.5 4 79.1 >4 >4 33.8
2004 34 0.25 0.32 96.8 0.25 0.25 98.8 0.5 4 80.0 >4 >4 32.7
TMP-SMX 2000 71 47.1 68.5 49.7 22.4
2001 50 42.6 66.3 43.6 23.6
2002 56 38.2 60.8 41.1 19.7
2003 37 >4 >32 51.4 2 >4 71.6 6 >16 55.6 >32 >32 21.9
2004 34 >4 >32 37.5 2 >4 59.2 6 >16 40.7 >32 >32 18.7
Vancomycin 2000 71 100 100 100 100
2001 50 100 100 100 100
2002 56 100 100 100 100
2003 37 0.12 0.25 100 – – 100 – – 100 – – 100
2004 34 0.12 0.25 100 – – 100 – – 100 – – 100
TMP-SMX, trimethoprim-sulphamethoxazole.
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infection was the respiratory tract. Most isolates
were obtained from sputum (47.9% of S. pneumo-
niae and 42.4% of H. inﬂuenzae isolates during the
5-year period) and nasal specimens (26.7% of
S. pneumoniae and 26.4% of H. inﬂuenzae isolates).
H. inﬂuenzae was isolated from throat cultures
more frequently than was S. pneumoniae, whereas
the latter was found more frequently in blood. In
general, the patterns of specimen types were more
or less stable during the 5-year period.
The isolation rate of S. pneumoniae was more
homogenous across the 12 months of the year
compared with H. inﬂuenzae, which had the high-
est numbers of isolates in January, March and
May. Approximately 66% of H. inﬂuenzae isolates
were obtained during the ﬁrst 6 months of each
year, with peaks during January, February and
March. Both organisms were isolated rarely in
September, the month of inﬂuenza vaccination,
which seems to be the end-point of a previous
cycle and the starting point of a new cycle.
Tables 1 and 2 summarise the in-vitro activities
of the antimicrobial agents tested against the
S. pneumoniae and H. inﬂuenzae isolates. The per-
centage of penicillin G non-susceptible S. pneumo-
niae isolates varied between 50 and 61.1%.
Susceptibility to clindamycin and erythromycin
decreased from 94.1% and 89.7% in 2000 to 75%
and 71.9% in 2004, respectively. All isolates were
susceptible to ceftriaxone, ciproﬂoxacin and
Table 2. Antimicrobial susceptibilities and MICs for 326 isolates of Haemophilus inﬂuenzae from the Saint George Hospital,
Beirut, between 2000 and 2004
Antibiotic Year n
All isolates b-Lactamase negative b-Lactamase positive BLNAR
MIC50 (mg ⁄L) MIC90 (mg ⁄L) % susceptible MIC50 (mg ⁄L) MIC90 (mg ⁄L) MIC50 (mg ⁄L) MIC90 (mg ⁄L) MIC50 (mg ⁄L)
Amox-clav 2000 61 100
2001 76 100
2002 66 100
2003 67 0.5 0.5 100 0.5 0.5 0.5 1 0.5
2004 56 0.5 0.5 100 0.5 0.5 0.5 1 1
Ampicillin 2000 61 69.2
2001 76 76.0
2002 66 70.3
2003 67 1 >16 66.7 0.5 1 >16 >64 8
2004 56 2 >16 65.5 0.5 1 >16 >64 16
Ceftriaxone 2000 61 100
2001 76 100
2002 66 100
2003 67 £0.004 0.03 100 £ 0.004 0.016 £0.004 0.03 0.25
2004 56 £0.004 0.03 100 £ 0.004 0.016 £0.004 0.03 0.25
Cefuroxime 2000 61 94.7
2001 76 92.1
2002 66 100
2003 67 1 2 98.2 0.5 1 1 4 16
2004 56 1 1.5 100 0.5 1 2 4 16
Tetracycline 2000 61 98.1
2001 76 98.6
2002 66 100
2003 67 0.25 £0.5 98.3 £0.25 0.5 1 1
2004 56 £0.25 £0.5 100 £0.25 1 1 1
TMP-SMX 2000 61 50.8
2001 76 50.0
2002 66 47.5
2003 67 12 32 56.9 1 8 >16 >32
2004 56 16 32 56.4 2 8 >16 >32
Ciproﬂoxacin 2000 61 100
2001 76 100
2002 66 100
2003 67 £0.004 0.008 100 £0.004 0.008 0.004 0.015
2004 56 £0.004 0.008 100 £0.004 0.008 0.004 0.015
Rifampicin 2000 61 100
2001 76 100
2002 66 100
2003 67 0.12 0.12 100 £0.12 0.12 0.12 0.25
2004 56 0.12 0.12 100 £0.12 0.12 0.12 0.25
Erythromycin 2000 61 96.5
2001 76 94.6
2002 66 96.9
2003 67 2 4 100 2 4 2 4
2004 56 2 4 100 2 4 4 8
The percentages of b-lactamase-positive isolates (not shown in the table) were 30.8%, 22.7%, 28.2%, 30.4% and 29.2% in 2000, 2001, 2002, 2003 and 2004, respectively.
b-Lactamase-positive, ampicillin-resistant (BLNAR) isolates comprised 1.3% of isolates in 2001, 1.5% in 2002, 2.9% in 2003, and 5.3% in 2004.
Amox-clav, amoxycillin-clavulanate; TMP-SMX, trimethoprim-sulphamethoxazole.
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vancomycin. It was interesting to note that the
erythromycin non-susceptible S. pneumoniae iso-
lates in 2000, 2001 and 2002were isolated from two,
four and two patients, respectively, of whom six
were paediatric patients (aged <5 years).
The MICs of most of the antimicrobial agents
tested remained constant. Internationally, the
percentage of erythromycin non-susceptible
S. pneumoniae isolates varies between 30 and
33% [4]. This increase in resistance to macrolides
has cast doubt on the efﬁcacy of these compounds
for the treatment of serious pneumococcal infec-
tions. Based on surveillance data from the Euro-
pean Antimicrobial Resistance Surveillance
System [13] and on outpatient sales of b-lactam
antibiotics and macrolides, a clear correlation
between antimicrobial resistance in S. pneumoniae
and use of macrolides was found in Europe. Most
pneumococcal strains which are macrolide-resist-
ant are also resistant to penicillin G.
All H. inﬂuenzae isolates were susceptible to
amoxycillin-clavulanate, ceftriaxone, oﬂoxacin,
perﬂoxacin and rifampicin. This activity was
maintained during the 5-year period of the study.
In comparison, ‡92% of isolates were susceptible
to chloramphenicol, erythromycin and tetracyc-
line during the study period. Trimethoprim-
sulphamethoxazole (TMP-SMX) was the least
active antimicrobial agent against H. inﬂuenzae,
with c. 50% susceptibility during the 5-year
period. MIC50 and MIC90 values for this drug
were high, particularly among b-lactamase-posit-
ive isolates. In 2003 and 2004, 21 (72.4%) and 19
(79.2%), respectively, of the TMP-SMX-resistant
isolates produced b-lactamase; the MIC90 value
for these isolates was 64 mg ⁄L in both 2003 and
2004. The percentage of b-lactamase-positive
H. inﬂuenzae isolates increased gradually during
the 5-year period of the study.
The frequency of b-lactamase production among
H. inﬂuenzae isolates was higher in the present
study compared with some other international
studies that reported an average of 12.6% [14].
However, Blosser-Middleton et al. [7] reported
frequencies similar to the present study for France
(27.6%) and Spain (33%). Ampicillin resistance
among non-b-lactamase-producing H. inﬂuenzae
isolates in the present study varied between 1.3%
in 2001 and 5.3% in 2004 (Table 2). Although the
identiﬁcation of BLNAR H. inﬂuenzae was only
preliminary, cefuroxime MICs for these isolates
were consistently >16 mg ⁄L.
The present study may serve as a prototype for
epidemiological surveys to be conducted at a
national level in Lebanon and other countries in
the Middle East in order to make an appropriate
assessment of local antimicrobial resistance pat-
terns. Such surveys are essential for informing any
policy aiming to contain antimicrobial resistance.
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ABSTRACT
In total, 151 newly diagnosed patients with
smear-positive pulmonary tuberculosis were
studied. The mean time from the onset of symp-
toms to the ﬁrst visit to a physician was 46.4 days;
the mean referral delay was 28.9 days; the mean
delay in diagnosis was 2.4 days; and the mean
delay in treatment initiation was 0.8 days. There
was a delay in consulting a physician by 49% of
patients. A low index of suspicion for tuberculosis
on the part of the physician and healthcare system
and laboratory delays were the most common
reasons for delays in diagnosis.
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Despite efforts to control tuberculosis, the disease
remains a major health problem worldwide. It is
estimated that the annual number of newly
diagnosed cases increased from 7.5 million in
1990 to 11.9 million in 2005; i.e., a 58.6% increase
during a 15-year period [1]. Among communic-
able diseases, tuberculosis is the second most
common cause of death worldwide [2], with an
estimated 19–43% of the world’s population
infected with Mycobacterium tuberculosis [3].
Spread of M. tuberculosis is predominantly by
patients with pulmonary tuberculosis, and it is
believed that smear-positive cases are more infec-
tious than smear-negative cases [4].
The key components of any tuberculosis control
programme are early diagnosis and prompt insti-
tution of effective therapy. This is especially
important for cases of smear-positive pulmonary
tuberculosis because they are the most important
reservoir for the transmission of infection in a
community [5]. It is estimated that an untreated
patient with smear-positive disease may infect
10–14 individuals annually [6]. Delays in diagno-
sis and treatment result in a prolonged period of
infectivity in the community [5,7], and are a
common problem in both developed and devel-
oping countries [5,7–11]. The present study inves-
tigated patterns and reasons for delays among
patients with smear-positive pulmonary tubercu-
losis in Turkey.
The study was conducted at the Heybeliada
Center for Chest Disease and Thoracic Surgery
(Istanbul, Turkey) between January andMay 2004.
In total, 151 newly diagnosed patients with smear-
positive pulmonary tuberculosiswere studied. The
clinical ﬁles of the patients were analysed and a
questionnaire was completed to obtain data con-
cerning age, gender, educational level, economic
status, presence of index case for tuberculosis,
presence of co-morbidity, and appearance of ﬁrst
symptoms. The various intervals and delays in
diagnosis (Fig. 1)were determined for each patient.
Patient application intervals that exceeded 30 days
were considered to be a patient delay. Referral
intervals that exceeded 2 dayswere regarded as an
institutional delay. Diagnosis intervals that excee-
ded 1 daywere considered to be a delayed diagnosis.
Treatment intervals that exceeded 1 day were
recorded as a delayed treatment [9,10,12]. The chi-
square test, ANOVA test or Student’s t-test were used
to assess differences between groups.
The study population comprised 84 (55.6%)
males and 67 (44.4%) females; the mean age
was 30.4 years (range 14–70 years). The delays
associated with the various stages in diagnosis
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